Kang Cheng, Chen-Fu Liu and Guo-Wu Rao* Pages 2540 - 2564 ( 25 )
Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis.
Tumor, anti-angiogenic agents, tyrosine kinase, VEGFR-2 inhibitor, approved drugs, synthesis.
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014